Document:

EX-10.16.2

 Exhibit 10.16.2 

Confidential Treatment Requested by Homology Medicines, Inc. 
  

 FIRST AMENDMENT TO LICENSE AGREEMENT 

This amendment to the License Agreement (the “First License Amendment”), effective on the date last signed below, (“Amendment Effective
Date”) is by and between Homology Medicines, Inc., a Delaware corporation having a place of business at 45 Wiggins Avenue, Bedford, MA 01730 (“HMI”) and California Institute of Technology, a not-for-profit corporation duly organized and existing under the laws of the State of California with an address at 1200 East California Boulevard, MC 6-32, Pasadena,
California 91125 (“Caltech”; HMI and Caltech together are the “Parties”). 
 Whereas, HMI and Caltech entered into that certain
License Agreement, effective September 9, 2016 (the “Agreement”); 
 Whereas, Caltech and the
Co-exclusive Licensee, as defined by the Agreement, entered into a Co-exclusive License, as defined by the Agreement, that grants the same rights to the Co-exclusively Licensed Patent Rights, as defined in the Agreement, as those granted to HMI; and 
 Whereas, HMI
and Caltech desire to amend the Agreement as set forth in this First License Amendment. 
 Now therefore, in consideration of the mutual covenants contained
herein, and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows: 
  

	 	1.	Section 1.19 is deleted in its entirety and replaced with the following: 

“Technology” means Verified [***], including reports 

that detail or describe the Verification of [***], from the laboratories Professor [***] or Professor [***] that are provided to Licensee by
Caltech pursuant to this Agreement, whether or not patentable, and as set forth in Exhibit B, as the same may be updated from time to time pursuant to Section 7.3. 

  
 Page 1 of 6

 First License Amendment | HMI | A3916-1 
 Confidential
Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission 

 Confidential Treatment Requested by Homology Medicines, Inc. 

 

	 	2.	It is understood that Caltech’s patent counsel determined that Caltech’s employee, Professor [***], made an inventive contribution to certain patent applications found in Exhibit A, specifically, patent
applications having serial numbers [***]. Furthermore, Caltech’s patent counsel has filed formal paperwork with the pertinent patent offices to have Professor [***] added as an inventor on said patent applications, and the Parties wish Exhibit
A to reflect this inventor addition. Therefore, the name [***] shall be added to the list of inventors for the aforementioned patent applications of Exhibit A. 

  

	 	3.	The following patent applications shall be added to Exhibit A: 

 [***] 

 

	 	4.	Accordingly, Exhibit A to the Agreement is hereby amended and replaced in full with Exhibit A (Amended) as attached hereto. 

  

	 	5.	The following sections are hereby inserted after Section 9.1 of the Agreement: 

 “9.1A
Caltech hereby covenants, represents and warrants to Licensee: 
 (a) that the Co-exclusive Licensee
to the Co-Exclusively Licensed Patent Rights will, or has already, entered into an identical first amendment to their Co-exclusive License (the “Third
Party First Amendment”), and that said Third Party First Amendment shall have the same effect on the Co-exclusive License as those amendments herein shall have on the Agreement; 

(b) that Caltech has secured Caltech’s ownership rights for the Licensed Patent Rights, as defined in the Agreement, including the rights
afforded by Professor [***] as an inventor, and that [***] has assigned to Caltech all her right, title and interest in the Licensed Patent Rights; 

  
 Page 2 of 6

 First License Amendment | HMI | A3916-1 
 Confidential
Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission 

 Confidential Treatment Requested by Homology Medicines, Inc. 

 

 (c) that Caltech will add [***] as an inventor to certain patent applications in the Licensed
Patent Rights as indicated in Exhibit A (Amended) and that, upon such addition, the inventorship of the patents and patent applications in the Licensed Patent Rights will be correct to the best of Caltech’s Office of Technology
Transfer & Corporate Partnerships knowledge; 
 (d) that all Technology developed in the laboratories of Professor [***] or
Professor [***] as of the date thirty (30) days after the Effective Date has been provided to Licensee in accordance with Section 7.3. 
  

	 	6.	Caltech shall assume responsibility for legal issues arising out of the inventorship change detailed in this First License Amendment. 

 

	 	7.	The last sentence of Section 11.1 of the Agreement is hereby amended to read as follows: 

“Licensee agrees not to disclose Technology or reports provided pursuant to Section 7.3 to any third party except to the extent the
information therein has been published, provided that Licensee may disclose such Technology and/or reports, and/or the terms of this Agreement, to actual or potential investors, actual or potential strategic partners, Affiliates, Sublicensees,
consultants, contractors or those under reasonable confidentiality obligations and whose receipt of said information is necessary for Licensee’s business activities.” 

  
 Page 3 of 6

 First License Amendment | HMI | A3916-1 
 Confidential
Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission 

 Confidential Treatment Requested by Homology Medicines, Inc. 

 

	 	8.	All other terms and conditions of the Agreement that are not modified or amended pursuant to this First License Amendment shall remain in full force and effect and unaffected hereby. This First License Amendment along
with the Agreement and all applicable exhibits, constitutes the complete agreement of the Parties concerning the subject matter hereof, and supersedes any other agreements, promises, representations or discussions, written or oral, concerning such
subject matter. This First License Amendment may be executed in several counterparts, all of which taken together shall constitute one single agreement between the Parties. This First License Amendment will be of no force or effect until signed by
an authorized representative of each of the Parties. After the Amendment Effective Date, every reference in the Agreement to the “Agreement” shall mean the Agreement as amended by this First License Amendment. 

  
 Page 4 of 6

 First License Amendment | HMI | A3916-1 
 Confidential
Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission 

 Confidential Treatment Requested by Homology Medicines, Inc. 

 

 In witness whereof, the duly authorized representatives of each of the parties hereto executed this First
License Amendment. 
  

							
	CALIFORNIA INSTITUTE OF TECHNOLOGY	  	HOMOLOGY MEDICINES, INC.
				
	By:	  	/s/ Frederic Farina	  	By:	  	/s/ Sam Rasty
		  	(Authorized Signature)	  		  	(Authorized Signature)
				
	Name:	  	Frederic Farina	  	Name:	  	Sam Rasty
				
	Title:	  	 Chief Innovation & Corporate

Partnerships Officer
	  	Title:	  	Chief Operating Officer
	Date:	  	May 16, 2017	  	Date:	  	May 3, 2017

  
 Page 5 of 6

 First License Amendment | HMI | A3916-1 
 Confidential
Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission 

 Confidential Treatment Requested by Homology Medicines, Inc. 

 

 Exhibit A (Amended) 

Licensed Patent Rights 
 [***] 

  
 Page 6 of 6

 First License Amendment | HMI | A3916-1 
 Confidential
Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange CommissionEX-10.16.3

 Exhibit 10.16.3 

Confidential Treatment Requested by Homology Medicines, Inc. 
  

 

 
 Confidential 

November 14, 2017 
 California Institute of
Technology 
 1200 East California Boulevard 
 Mail Code 6-32 
 Pasadena, CA 91125 

Attention: Chief Innovation & Corporate Partnerships Officer 

Novartis Institutes for BioMedical Research, Inc. 
 250
Massachusetts Avenue 
 Cambridge, MA 02139 
 Attention:
President, Novartis Institutes for BioMedical Research, Inc. 
 Re: Amendment and Stand-by License Arrangement
with Novartis Institutes for BioMedical Research, Inc. (“NVS”) 
 Ladies and Gentlemen: 

Reference is hereby made to that certain License Agreement dated September 14, 2016 by and between Homology Medicines, Inc. (“HMI”) and
the California Institute of Technology (“Caltech”), as amended by the First Amendment to License Agreement dated May 16, 2017 (the “Caltech-HMI License”). All capitalized
terms used but not defined herein will have the meaning set forth in the Caltech-HMI License. 
 This letter
agreement (this “Letter Agreement”) serves as the second amendment to the Caltech-HMI License, effective on the date last signed below. HMI and Caltech agree as follows: 

The fifth paragraph of Section 2.3 (Sublicensing) of the Caltech-HMI License is hereby deleted and
replaced in its entirety with the following: 
 “Any sublicenses granted by Licensee shall survive termination of the licenses granted
in Section 2.1 or termination of this Agreement, provided that the following conditions are met as of the date of such termination: 

(a) the written agreement between Licensee and Sublicensee pursuant to which the sublicense was granted (i) [***], (ii)
[***], and (iii) [***]; 

  
 1 

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with
the Securities and Exchange Commission. 

 Confidential Treatment Requested by Homology Medicines, Inc. 

 

 (b) Licensee informs the Sublicensee in writing (with a copy to Caltech) that
the Sublicensee’s obligations pursuant to the foregoing clause (a) are in effect as a result of the termination; and 

(c) the sublicense was granted in accordance with the sublicensing provisions of this Agreement.” 

In addition, HMI proposes to enter into an agreement (the “Collaboration Agreement”) with NVS pursuant to which, among other things, HMI
grants to NVS an exclusive sublicense of the rights licensed to HMI by Caltech under the Caltech-HMI License (the “Licensed Caltech Rights”) with respect to certain candidates and products (as
defined under the Collaboration Agreement, “Candidates” and “Products”) as well as other patent rights and know-how controlled by HMI. As a condition to entering into the
Collaboration Agreement, NVS has requested that Caltech and HMI memorialize, in this Letter Agreement, their agreement to the following: 
  

	1.	Term. The following provisions of this Letter Agreement will be effective as of the date of this Letter Agreement, but will be null and void if the Collaboration Agreement is not executed by each of HMI and NVS
within [***] days after the date of this Letter Agreement. 

  

	2.	Approval of Sublicense; Delivery of Collaboration Agreement. Caltech hereby acknowledges that HMI may grant a sublicense of the Licensed Caltech Rights and stipulates that the version of the Collaboration
Agreement provided to Caltech grants to NVS a sublicense of the Licensed Caltech Rights in accordance with the sublicensing provisions of the Caltech-HMI License, as required under Section 2.3
(Sublicensing) of the Caltech-HMI License (as amended pursuant to this Letter Agreement), and the parties agree that the final version of the Collaboration Agreement will remain consistent with
Section 2.3 (Sublicensing) of the Caltech-HMI License. HMI will deliver to Caltech a true and complete copy of the Collaboration Agreement promptly following the execution thereof, which copy,
notwithstanding to the contrary set forth in Section 2.3 (Sublicensing) of the Caltech-HMI License, may be redacted to remove any confidential, proprietary, or competitive information of HMI or NVS to the
extent that such redactions do not impair Caltech’s ability to ensure that the Collaboration Agreement is consistent with the Caltech-HMI License. 

 

	3.	No Breach. Caltech confirms that as of the date of this Letter Agreement: (a) the Caltech-HMI License remains in full force and effect; and (b) Caltech has not
given any notice to HMI of any breach by HMI under the Caltech-HMI License. 

  

	4.	Waiver of Sublicense Obligations. 

  

	 	(a)	Caltech hereby irrevocably waives [***] and confirms that HMI will be in compliance with [***]. 

  
 2 

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with
the Securities and Exchange Commission. 

 Confidential Treatment Requested by Homology Medicines, Inc. 

 

	 	(b)	Caltech hereby waives the requirement in [***], provided however, that: 

  

	 	i.	NVS and Caltech promptly execute an agreement memorializing Caltech’s adoption, as the licensor, of the sublicense to the Licensed Caltech Rights under the Collaboration Agreement should the licenses granted in
Section 2.1 (Grant of Rights) of the Caltech-HMI License or the Caltech-HMI License terminate; and 

 

	 	ii.	in the event of a conflict between the terms, conditions or obligations under the Caltech-HMI License and the Collaboration Agreement (except as specifically waived under this
Letter Agreement) with respect to the Licensed Caltech Rights, the terms of the Caltech-HMI License will prevail. 

  

	5.	Assignment of Caltech-HMI License. Caltech agrees that if it assigns its rights under the Caltech-HMI License or any of the
intellectual property licensed to HMI thereunder, then Caltech will cause the applicable assignee to be bound by the terms of this Letter Agreement applicable to Caltech. 

 

	6.	Notices. Any notices required or permitted under this Letter Agreement will be in writing, will specifically refer to this Letter Agreement, and will be sent by recognized national overnight courier, or
registered or certified mail, postage prepaid, return receipt requested, to the following addresses: 

 If to
Caltech:     
 California Institute of Technology 

1200 East California Boulevard 
 Mail Code 6-32 
 Pasadena, CA 91125 

Attention: Chief Innovation Officer 
 If to HMI: 

Homology Medicines, Inc. 
 45 Wiggins Avenue 

Bedford, MA 01730 
 Attention: Chief Operating Officer 

If to NVS:     
 Novartis Institutes
for BioMedical Research, Inc. 
 250 Massachusetts Avenue 

Cambridge, MA 02139 
 Attention: General Counsel. 

  
 3 

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with
the Securities and Exchange Commission. 

 Confidential Treatment Requested by Homology Medicines, Inc. 

 

 All notices will be deemed effective: (a) if by courier, on the Business Day (as defined under the
Collaboration Agreement) of delivery as evidenced by the courier’s receipt (or if delivered or sent on a non-Business Day, then on the next Business Day); or (b) if sent by registered or certified
mail, on the Business Day of receipt as evidenced on the return receipt. Caltech, HMI or NVS may change its contact information immediately upon written notice to the other party in the manner provided in this Section 6 (Notices). 

 

	7.	Miscellaneous. 

  

	 	(a)	Governing Law. This Letter Agreement will be construed and interpreted in accordance with the laws of the State of California and all rights and remedies will be governed by such laws without regard to principals
of conflicts of law. The exclusive jurisdiction of any such suit shall be the state and federal courts located in Los Angeles County, California, and the parties hereto consent to the exclusive jurisdiction and venue of such courts.

  

	 	(b)	Amendment. Changes and additional provisions to this Letter Agreement will be binding on the parties only if agreed upon in writing and signed by all parties. 

 

	 	(c)	Assignment of this Letter Agreement. This Letter Agreement may not be assigned by any party without the prior written consent of the other parties, which consent may not be unreasonably withheld, except
that, a party may assign this Letter Agreement without such prior written consent to an affiliate or in connection with a merger, consolidation, sale of all of the equity interests of such party, or a sale of all or substantially all of the
assets of such party to which this Letter Agreement relates. 

  

	 	(d)	Confidentiality. The terms of this Letter Agreement will not be disclosed by any party hereto without the prior written consent of each of the other parties; provided, that each party will be entitled to
disclose the terms of this Letter Agreement to the extent permitted in Section 11.2 (Permitted Disclosures) of the Caltech-HMI License mutatis mutandis as if such Section were set forth in this
Letter Agreement and the terms of this Letter Agreement were Confidential Information of each of the parties. 

  

	 	(e)	Severability. The parties do not intend to violate any public policy or statutory common law. However, if any sentence, paragraph, clause, or combination of this Letter Agreement is in violation of any law or is
found to be otherwise unenforceable, such sentence, paragraph, clause, or combination of the same will be deleted and the remainder of this Agreement will remain binding, provided that such deletion does not alter the basic purpose and
structure of this Letter Agreement. 

  

	 	(f)	Independent Contractor. Nothing herein will create any association, partnership, joint venture, fiduciary duty, or the relation of principal and agent between the parties hereto, it being understood that each
party is acting as an independent contractor, and no party will have the authority to bind the others or the others’ representatives in any way. 

  
 4 

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with
the Securities and Exchange Commission. 

 Confidential Treatment Requested by Homology Medicines, Inc. 

 

	 	(g)	Further Assurances. Each party hereto agrees to execute, acknowledge, and deliver such further instructions, and to do all such other acts, as may be necessary or appropriate in order to carry out the purposes
and intent of this Letter Agreement. 

  

	 	(h)	Interpretation. This Letter Agreement has been prepared by all of the parties hereto and no rule of strict construction will be applied against any party. In this Agreement, the singular will include the plural
and vice versa and the word “including” will be deemed to be followed by the phrase “without limitation.” The section headings contained in this Letter Agreement are inserted for convenience only and will not affect in any way
the meaning or interpretation of this Letter Agreement. 

  

	 	(i)	Counterparts. This Letter Agreement may be executed in counterparts, each of which together will constitute one and the same Letter Agreement. For purposes of executing this Letter Agreement, a facsimile copy or
an emailed PDF of this Agreement, including the signature pages, will be deemed an original. 

  

	 	(j)	Entire Agreement. This Letter Agreement, the Caltech-HMI License, and the Collaboration Agreement, together with all exhibits and schedules attached hereto and
thereto, set forth the entire agreement with respect to the subject matter hereof and thereof and supersede all other agreements and understandings between the parties with respect to such subject matter. 

 

	 	(k)	Waiver. No delay on the part of any party hereto in exercising any power or right hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of any power or right hereunder
preclude other or further exercise thereof or the exercise of any other power or right. No waiver of this Letter Agreement or any provision hereof shall be enforceable against any party hereto unless in writing, signed by the party against whom such
waiver is claimed, and shall be limited solely to the one event. 

 [Remainder of this page intentionally left blank]

  
 5 

Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with
the Securities and Exchange Commission. 

 Confidential Treatment Requested by Homology Medicines, Inc. 

 

 Please sign and return a copy of this Letter Agreement to us to acknowledge each party’s agreement on
this matter. Thank you for all of your assistance. 
 Sincerely, 

HOMOLOGY MEDICINES, INC. 

     /s/ Arthur Tzianabos 

Name:  Arthur Tzianabos 

Title:    President and Chief Executive Officer 

ACKNOWLEDGED AND AGREED: 
 CALIFORNIA INSTITUTE
OF TECHNOLOGY 
      /s/ Fred Farina 

Name:  Fred Farina 
 Title:    Chief
Innovation & Corporate Partnerships Officer 
 NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 

     /s/ Scott A. Brown 

Name:  Scott A. Brown 

Title:    VP, General Counsel 

[Signature Page to Letter Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00280-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00280-of-00352.parquet"}]]